WO2020184992A1 - 세포 내 물질 전달을 위한 미세유체 시스템 및 방법 - Google Patents
세포 내 물질 전달을 위한 미세유체 시스템 및 방법 Download PDFInfo
- Publication number
- WO2020184992A1 WO2020184992A1 PCT/KR2020/003411 KR2020003411W WO2020184992A1 WO 2020184992 A1 WO2020184992 A1 WO 2020184992A1 KR 2020003411 W KR2020003411 W KR 2020003411W WO 2020184992 A1 WO2020184992 A1 WO 2020184992A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- microfluidic system
- fluid
- vortex
- Prior art date
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
- C12M27/02—Stirrer or mobile mixing elements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/14—Pressurized fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
- C12M33/10—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus by centrifugation ; Cyclones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0652—Sorting or classification of particles or molecules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
Definitions
- the present invention for intracellular substance delivery It relates to microfluidic systems and methods.
- Intracellular mass transfer is one of the most basic experiments in cell engineering, and transfers materials by using carriers or by making nanopores in the cell membrane/nuclear membrane.
- Virus or Lipofectamine-centered carrier techniques are optimized for highly efficient mass transfer when optimized. Although possible, there are problems such as safety, slow delivery speed, labor/cost intensive carrier preparation process, and low reproducibility.
- US Patent 2014-0287509 discloses a technology for inducing cell transformation rate by applying pressure to cells through a channel having a bottleneck structure.
- the cells block the bottleneck structure, and there is a problem that the material can be transferred only to cells smaller than the size of the constriction.
- high cost occurs in that a channel having a fine diameter must be used.
- the problem to be solved by the present invention is to provide a system and method capable of delivering substances with high efficiency to a large number of cells without the use of new active delivery means.
- the present invention is a microfluidic system for delivering foreign substances into cells by perforating cells using inertia, and includes a fluid channel structure in which a solution containing cells and foreign substances continuously flows, and the fluid channel
- the structure includes a junction between one or more channels, a local vortex occurs near the interface of the connection point, the cell is deformed by the vortex, and a temporary discontinuity of the cell membrane is created by the vortex, and the cell and the cell It provides a microfluidic system, characterized in that the foreign material is introduced into the cell according to the exchange of solutions between the surrounding fluids.
- the fluid channel structure when the fluid channel structure is a T or Y-shaped channel, it may include a cavity near the fluid stagnation point.
- the cavity may include a circle, an oval, an elongated slit, a square, a rectangle, a trapezoid, a polygon, a combination thereof, and a modified shape thereof.
- the diameter of the cavity is determined according to the diameter of the cell.
- the microfluidic system further includes a fluid control means for flowing a solution in the fluid channel structure, and the fluid control means is a level capable of generating a local vortex near the interface of the connection point.
- the solution can flow through the fluid channel at a rate.
- the fluid control means may be a syringe pump or a pneumatic system.
- the Reynolds number (Re) of the solution may be 1 to 1000.
- the vortex characteristic may be determined according to the Reynolds number.
- the vortex may be in the form of a closed or open recirculating flow.
- the microfluidic system may be a combination of the above-described systems in series, parallel, or a combination thereof.
- the present invention is also a method of delivering a foreign material into the cell by perforating cells using inertia, comprising: continuously flowing a solution containing the cells and the foreign material into a fluid channel; Forming a vortex by means of vortex generation means near the connection point; Transforming the cells by the eddy current; And introducing the foreign material into the cell through the perforation generated in the cell membrane by the cell deformation. It provides a method of delivering the foreign material into the cell by perforating the cell using inertia.
- the vortex generating means may be a connection point structure of the fluid channel.
- the fluid channel may include a connection point including a T, Y, cross shape, or a combination thereof.
- vortices are generated by flowing cells and foreign substances in a flow channel structure including at least one junction, and the cells are deformed with the inertia to induce a temporary discontinuous phase of the cell membrane, thereby perforating the cell membrane. Thereafter, a solution exchange occurs between the cell and the fluid around the cell through the perforated cell membrane, and as a result, the foreign material is introduced into the cell.
- the present invention does not require vectors or active cell delivery means (eg electric fields, etc.). Accordingly, the present invention can directly deliver foreign substances (ex: genes, plasmids, nanoparticles, etc.) into cells with high efficiency and low cost only with the characteristics of the solution and channel structure.
- 1 is a diagram showing the formation of a helical vortex in a ⁇ connection point channel.
- Fig. 2 is a schematic diagram (1) of cell deformation due to a spiral vortex and a high-speed microscope image (2) showing rotational cell motion (scale bar: 10 ⁇ m).
- FIG. 4 is a schematic diagram of two types of channel structures according to an exemplary embodiment of the present invention and a diagram for explaining cell deformation in each channel.
- FIG. 5 is a schematic diagram of a microfluidic system in which two types of fluid channels of FIG. 4 are connected in series in a fluid flow direction.
- FIG. 8 is a graph in which cell capture and cell transformation time according to the eddy current collapse of FIG. 7 are normalized as a function of Reynolds number.
- 10 to 12 are diagrams for explaining a method for delivering intracellular substances using the intracellular substance delivery platform according to an embodiment of the present invention.
- FIG. 13 is a schematic diagram of a T connection point structure channel according to an embodiment of the present invention.
- FIG. 14 is a high-speed microscopic image illustrating the mechanism of cell deformation and vortex formation in the T junction channel of the cavity structure.
- each of the arrows indicates the direction of fluid flow.
- 16 is a diagram showing an intracellular material delivery platform according to an embodiment of the present invention.
- 17 to 19 are diagrams for explaining a method for delivering intracellular substances using the intracellular substance delivery platform according to an embodiment of the present invention.
- 26 and 27 are photographs of analyzing the intracellular delivery effect of gold nanoparticles (GNP) and the results of counting scattering points.
- FIG. 29 is a result of calculating the normalized yield by multiplying the number of scattering spots by the cell survival rate (FIG. 5F).
- MSN menopausal silica nanoparticles
- FIG. 31 is a time-dependent cell viability analysis result of the analyte of FIG. 30.
- FIG. 32 is a histogram of fluorescence intensity measuring the transduction effect to K562 cells using mRNA (996-nucleotide mRNA fragment, green fluorescent protein) as a foreign material.
- 39 and 40 show the results of analyzing the ITGa1 gene knockdown effect by Western blot by delivering siRNA to HeLa cells ( ⁇ 1 subunit of the integrin transmembrane receptor) and comparing the relative expression levels.
- 45 is a confocal microscope image showing that quantum dots (qdot625) are transferred to MDA-MB-231 cells by the present invention ( ⁇ -Hydroporator), electroporator, and Lipofectamine 3000.
- 49 and 50 are confocal images for two of the groups of FIGS. 47 and 48.
- the present invention is a microfluidic system for delivering foreign substances into a cell by perforating cells using inertia, and includes a fluid channel structure in which a solution containing cells and foreign substances continuously flows,
- the fluid channel structure includes one or more junctions between channels, a local vortex occurs near the interface of the connection point, the cell is deformed by the vortex, and a temporary discontinuity of the cell membrane is created by the vortex. It provides a microfluidic system, characterized in that the foreign material is introduced into the cell according to the solution exchange between the cell and the fluid surrounding the cell.
- the present invention comprises the steps of continuously flowing a solution containing the cells and foreign substances into a fluid channel; Forming a vortex by means of vortex generation means near the connection point; Transforming the cells by the eddy current; And introducing the foreign material into the cell through the perforation generated in the cell membrane by the cell deformation. It provides a method of delivering the foreign material into the cell by perforating the cell using inertia.
- the present invention is a system for delivering foreign substances outside the cell into a cell, and has a microfluidic channel structure including at least one junction to which at least two channels are connected. It provides a microfluidic system.
- connection point refers to a point where each channel meets when two or more channels are connected in the form of T, Y, ⁇ or a combination thereof, and the connection point in the present invention is a single point defined as an inlet and an outlet of a fluid. There may be at least one or more in the channel.
- an SU-8 mold or a silicon wafer is etched through a photolithography process to first form a mold having a channel according to the present invention.
- a PDMS-based chip was made through polydimethylsiloxane (PDMS), and an inlet and an outlet were made on the chip, and by using a general slide glass and plasma treatment (Cute, Femto Science, South Korea) to manufacture a platform device.
- a general slide glass and plasma treatment (Cute, Femto Science, South Korea) to manufacture a platform device.
- a syringe pump After mixing the cells in the suspended state and the material to be delivered to the chip made, they are injected using a syringe pump.
- intracellular material delivery can be controlled by controlling the flow rate of the syringe pump, and after delivery, only the cells are separated using a centrifuge and then cultured again or analyzed or used according to the purpose.
- the scope of the present invention is not limited to the examples themselves.
- Example 1 ⁇ Connection point structure microfluidic system
- 1 is a diagram showing the formation of a helical vortex in a ⁇ connection point channel.
- the term "near" refers to a region in which a fluid introduced to a junction can generate a vortex due to a junction structure.
- Fig. 2 is a schematic diagram (1) of cell deformation due to spiral vortex and a high-speed microscope image (scale bar: 10 ⁇ m) showing rotational cell motion.
- FIG 3 is a diagram for explaining a mechanism of mass transfer according to cell transformation according to an embodiment of the present invention.
- nanopores are generated in the cell membrane according to cell deformation on the left side, and the foreign material is introduced into the cell according to the solution exchange between the cell and the fluid surrounding the cell. After that, within 1 to 10 minutes, the cell membrane self-recovers and closes, and this recovery time can be controlled by adjusting the concentration of an electrolyte such as calcium in the solution.
- FIG. 4 is a schematic diagram of two types of channel structures according to an exemplary embodiment of the present invention and a diagram for explaining cell deformation in each channel.
- FIG. 5 is a schematic diagram of a microfluidic system in which two types of fluid channels of FIG. 4 are connected in series in a fluid flow direction.
- the microfluidic system of the present invention includes (1) ⁇ cross junction and (2) a T connection point at which fluid induced while passing through a vortex from the ⁇ connection point structure channel collides with the channel wall. It has a rescue channel (T-Junction).
- the microfluidic structure in the form of T, Y, ⁇ may be designed in series, parallel, or a combination of fluid flows, all of which fall within the scope of the present invention.
- a plurality of connection points to which a plurality of unit channels are connected may be formed on a single channel defined as a cell reference inlet and an outlet.
- the system according to the present invention has a specific additional effect of capturing cells by vortex breakdown after cell transformation and mass transfer due to vortex formation and inducing transformation.
- a specific trapping phenomenon of cells was observed for a certain period of time as the cell deformed region due to the first vortex flow. That is, slightly above the stationary point, the cells repeatedly moved up and down for about 30 ⁇ s, and then went out to the exit again. This means that immediately after leaving the vortex region, the cell is deformed for a certain period of time according to the inertia caused by the vortex collapse and then stays in the region near the junction (the region near the stagnation point), and thereby the intracellular mass transfer efficiency can be greatly improved.
- FIG. 8 is a graph in which cell capture and cell transformation time according to the eddy current collapse of FIG. 7 are normalized as a function of Reynolds number.
- FIG. 9 is a diagram showing an intracellular mass transfer platform according to an embodiment of the present invention.
- the intracellular mass transfer platform includes: a first channel 100 through which a fluid including cells and a transfer material flows; A second channel 200 perpendicular to the first channel 100; And a first fluid control means 300 provided at one side of the first channel 100 to control a fluid velocity in the first channel 100 in a first direction.
- the fluid in the first channel 100 flows oppositely to a point perpendicular to the second channel 200, and the first fluid control means 300 A kinetic energy applied to the cells on the first channel 100 by applying cell membrane deformation at a level at which nanopores are formed in the cells by the vortex formed at the point where the first channel 100 and the second channel 200 intersect vertically Characterized in that.
- the other side of the first channel 100 may further include a second fluid control means 300 ′ for controlling the fluid velocity in the first channel 100 in a second direction.
- first and second fluid control means (300, 300') controlled in opposite directions in the first channel (100) at a point where the first channel (100) and the second channel (200) cross each other perpendicularly. It may be formed, and physical deformation is applied to the cell by the inertial force and the inertial flow phenomenon generated accordingly, so that the cell membrane may be deformed.
- the intracellular material delivery platform according to the present invention can deliver nucleic acids, proteins, transcription factors, vectors, plasmids, genetic scissors material, nanoparticles, and the like. However, it is not limited thereto.
- the intracellular substance delivery platform is not limited to regenerative medicine, cancer immunotherapy, gene editing, or application to other fields.
- 10 to 12 are diagrams for explaining a method for delivering intracellular substances using the intracellular substance delivery platform according to an embodiment of the present invention.
- the fluid including the cells and the delivery material flows through the first channel 100 by the first fluid control means 300.
- the second fluid control means 300 ′ formed on the other side of the first channel 100 also operates, so that the delivery material can flow in a direction facing the fluid controlled by the first fluid control means 300. .
- the delivery material includes all materials that can be delivered into cells, and specifically, a genetic scissors material, a plasmid, a nucleic acid, a protein, a nanoparticle, etc. may all correspond to this.
- another cell deformation is induced according to a vortex breakdown formed after passing through a vortex formed in the fluid.
- Example 2 T or Y connection point structure microfluidic system
- a cavity is an empty space formed in a channel at a point of congestion, and is a structure that eliminates or reduces the collision area between the cell and the channel wall when the cell of the solution and the channel wall collide at the connection point.
- FIG. 13 is a schematic diagram of a T connection point structure channel according to an embodiment of the present invention.
- the cells Upon injection, the cells were concentrated in the center of the channel by inertia, and the cells collided with the channel wall. Each cell partially penetrates the above-described cavity (Fig. 13 (1)), and has been deformed (see the right photo of Fig. 13). Subsequently, after the first cell transformation according to the collision, the cells are captured in a local vortex near the stagnation point (point (2) in FIG. 13), and are hydrodynamically deformed, forming nanopores in the cell membrane, which are described in FIG. As shown.
- a cavity is used in the T connection point channel structure, and the advantage is that cells can collide in a fluid form instead of a hard solid channel wall, thereby reducing cell damage due to collision with the hard solid channel wall. It is to let. Another is to form a stagnation point upstream of the incoming stream, supporting complex fluid behavior patterns, virtually preventing cell clogging. Therefore, the shape, size, shape, etc. of this cavity structure may vary depending on the cell. For example, as shown in FIG. 13, it may include not only a circular, elliptical, elongated slit, square, rectangular, trapezoidal, polygonal, combination thereof, and a modified form thereof, as shown in FIG. As long as they do not collide with, they all belong to the cavity of the present invention.
- the cavity diameter is determined according to the cell diameter, and in particular, it is preferable to have a diameter of 10% to 5 times the cell size.
- the cavity diameter according to the present invention is at least within the scope of the present invention as long as it can reduce the collision force caused by collision of the cells flowing into the connection point with the channel wall through the solution.
- FIG. 14 is a high-speed microscopic image illustrating the mechanism of cell deformation and vortex formation in the T junction channel of the cavity structure.
- each of the arrows indicates the direction of fluid flow.
- VDI Vortex Deformation Index
- t is the cell capture time in the vortex and c is the circularity ( , Where A and P are the area and radius at maximum strain), U is the average velocity of the fluid, and D is the cell diameter.
- 16 is a diagram showing an intracellular material delivery platform according to an embodiment of the present invention.
- Intracellular mass transfer platform comprises a third channel 101 forming a path through which a fluid containing cells and a transfer material moves; A fourth channel 201 extending vertically to both sides of the third channel 101 at an end of the third channel 101; And a fluid control means 301 provided in the third channel 101 to control a fluid velocity in the third channel 101.
- 17 to 19 are diagrams for explaining a method for delivering intracellular substances using the intracellular substance delivery platform according to an embodiment of the present invention.
- the fluid including the cells and the delivery material flows through the third channel 101 by the fluid control means 301.
- the delivery material includes all materials that can be delivered into cells, and includes all materials such as scissor materials, plasmids, nucleic acids, proteins, and nanoparticles.
- the cells of the third channel 101 accelerated by the fluid control means 301 are trapped by a vortex formed near a connection point and then deformed. This is as described in FIGS. 13 and 14. Thereafter, the cells collide with the partition wall of the fourth channel 201 connected to the end of the third channel 101.
- the fourth channel 201 is provided with a slit-shaped cavity 401 formed in the same direction as the fluid flow direction in the third channel 101, and the cavity 1) prevents cell damage due to physical collision. 2) Prevent clogging 3) It causes the effect of forming stagnation points in the upstream.
- a plurality of unit microfluidic systems may be connected in series or in parallel, or a combination thereof to construct an entire system.
- the vortex in a circulating manner, the vortex may occur in a recirculated flow, in which case the vortex may be a closed or open flow.
- the intracellular mass transfer effect according to the present invention can be confirmed through multiple FITC signals on the right.
- FIG. 24 is a result of measuring dextran delivery efficiency in the complex microfluidic system of FIG. 5 (a combination of a connection point channel and a T connection point channel).
- 25 is a comparison result of the transfer efficiency of the conventional electroporation (electroporation, a Neon Transfection System (Thermo Fisher Scientific, Waltham, MA, USA)) and the inertial-based material transfer method (hydroporation) according to the present invention.
- electroporation electroporation, a Neon Transfection System (Thermo Fisher Scientific, Waltham, MA, USA)
- hydroporation inertial-based material transfer method
- the present invention in the case of 2000 kDa FITC-dextran, the present invention was 4 times higher than that of the electroporation method.
- the method according to the present invention greatly improves the delivery efficiency of macromolecules that are difficult to penetrate into cells by the electroporation method, which suggests the possibility of intracellular delivery of molecular weight substances that cannot be achieved by conventional electroporation techniques.
- FIGS. 26 and 27 are photographs of analyzing the intracellular delivery effect of gold nanoparticles (GNP) and the results of counting scattering points.
- GNP gold nanoparticles
- (A) is the result of the hydrodynamic drilling method (SH),
- GNP can be delivered by electroporation, but it can be seen that only a few scattering points are detected (B). Furthermore, the endocytosis mechanism showed lower particle transfer efficiency than electroporation (C).
- the intracellular mass transfer method and system according to the present invention have a higher survival rate than the electroporation method.
- FIG. 29 is a result of calculating the normalized yield by multiplying the number of scattering spots by the cell survival rate (FIG. 5F).
- MSN menopausal silica nanoparticles
- DOX anti-containing drug doxorubicin
- FIG. 31 is a time-dependent cell viability analysis result of the analyte of FIG. 30.
- DOX cytotoxicity to MDA-MB-231 cells was measured by the trypan blue exclusion method, and it can be seen that approximately 85% of cancer cells died after 6 hours. From these results, it is indicated that the microfluidic system according to the present invention can investigate DOX-induced apoptosis without using a conventional surface ligand-based DOX delivery method.
- FIG. 32 is a histogram of fluorescence intensity measuring the transduction effect to K562 cells using mRNA (996-nucleotide mRNA fragment, green fluorescent protein) as a foreign material.
- mRNA 996-nucleotide mRNA fragment, green fluorescent protein
- FIG. 32 (A) is endocytosis, (B) is the microfluidic system result according to the present invention, EGFP protein expression was evaluated based on mRNA delivery (2 ⁇ g / mL) using a flow cytometer.
- the method according to the present invention shows a very high protein expression level. This means that the intracellular substance delivery method and system according to the present invention can be used for chimeric antigen (CAR-T) without the use of vectors or vaccines.
- CAR-T chimeric antigen
- the method according to the present invention detected a strong EGFP signal resulting from higher mRNA delivery efficiency.
- DNA Unlike mRNA, which first binds to the cell substrate, DNA must first pass through the cell membrane and enter the nuclear membrane through the nuclear pore. Furthermore, in terms of mass transfer, naked plasmid DNA is easily degraded by nucleases and has a high viscosity. And high-density cytoplasm does not provide good conditions for long and twisted DNA to go to the nucleus by pure diffusion.
- the present inventors provide a fluid-based microfluidic system according to the present invention as a method of delivering plasmid DNA to the nucleus. To this end, in this experimental example, an experiment was performed to encode copepod GFP and deliver 7.9 kbp plasmid DNA to HEK293t cells.
- the method according to the present invention shows a very strong fluorescence image.
- FIG 38 is a graph showing the analysis of the plasmid DNA (pDNA) transformation efficiency of HEK293t cells (E (and the average intensity (F) of the average HEK293t cells according to the plasmid DNA concentration).
- 39 and 40 show the results of analyzing the ITGa1 gene knockdown effect by Western blot by delivering siRNA to HeLa cells ( ⁇ 1 subunit of the integrin transmembrane receptor) and comparing the relative expression levels.
- the ITGa1 gene knockdown effect was compared using a conventional cationic Lipofectamine 3000 known as a siRNA delivery method as a comparative example.
- mRNA was selected as a delivery target, because after mRNA delivery, protein expression is expressed in the cytoplasm and induced to fat, and it can be well controlled, and it is easy to compare according to the amount-dependent transformation.
- EGFP mRNA was converted to MSC (harton's jelly human umbilical cord mesenchymal stem cell), ADSC ( human adipose derived stem cell), and BMDC (mouse bone marrow derived dendritic cell).
- the present invention shows a very high trait yield compared to Lipofectamine 3000 and the electroporation method.
- the trait yield is defined as the product of the transformation efficiency and the cell viability, and this can be understood as the ratio of viable cells to cells transformed by material transfer.
- lipofection showed improved cell viability compared to the present invention ( ⁇ -Hydroporator) and electroporation in all cell types, but it can be seen that substantially low transformation efficiency was shown in all cell types. have.
- transformation efficiency was slightly higher in electroporator than in the present invention ( ⁇ -Hydroporation).
- the present invention ⁇ -Hydroporator
- the cell viability of the present invention may be further increased by simply adding trehalose or a polymer to the cell medium.
- the present invention showed higher transformation efficiency and cell survival rate than the electroporation method, which shows that the present invention is highly likely to be used in cancer immunotherapy.
- the present invention can process up to 1 x 106 cells/min while maintaining the same level of delivery efficiency, and since this throughput is based on a single microchannel, the cell throughput required for cancer immunotherapy through multiplexing and parallelization of microchannels You can run.
- quantum dots Dibenzo cyclooctyne (DOBI)
- silica nanospheres which are widely used as target molecules, were determined as intracellular delivery materials, and the delivery characteristics to the cells (MDA-MB-231) were analyzed.
- 45 is a confocal microscope image showing that quantum dots (qdot625) are transferred to MDA-MB-231 cells by the present invention ( ⁇ -Hydroporator), electroporator, and Lipofectamine 3000.
- the result of this analysis shows the degree of aggregation of the quantum dots.
- the number of quantum dots per cell is the lowest. That is, electroporation or lipofection shows the number of quantum dots three and four times higher than that of the present invention.
- electroporation or lipofection shows the number of quantum dots three and four times higher than that of the present invention.
- Figure 47 is a negative control (untreated K562 cells, negative control), positive control (K562 cells cultured with nanospheres, the same time as in the Example, the same concentration) and the present invention ( ⁇ -Hydroporator) according to the nanospheres (green fluorescence)
- Figure 48 shows the results of measuring the relative average fluorescence intensity.
- 49 and 50 are confocal images for two of the groups of FIGS. 47 and 48.
- a DiD lipophilic carbosiamine dye was used to visualize the cell membrane.
- the green fluorescence signal from the positive control (co-culture) was present only in the cell membrane, but bright green fluorescence from the cytoplasm was observed only in the cells treated according to the present invention.
- microfluidic system for delivering foreign substances into cells by perforating cells using inertia is recognized for its industrial applicability in the fields of bio and medicine that require transfer of substances into cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Analytical Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Cell Biology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (16)
- 관성을 이용한 세포 천공에 의하여 외부 물질을 세포 내로 전달하는 미세유체 시스템으로,세포와 외부 물질을 포함하는 용액이 연속적으로 흐르는 유체채널 구조를 포함하고,상기 유체채널 구조는 하나 이상의 채널 간 연결점(junction)을 포함하며,상기 연결점 계면 근처에서 국소 와류가 발생하며,상기 와류에 의하여 세포는 변형되며,상기 와류에 의하여 세포막의 일시적 불연속성이 생성되며, 상기 세포와 세포 주변 유체 사이의 용액교환에 따라 상기 외부 물질이 상기 세포 내로 도입되는 것을 특징으로 하는 미세유체 시스템.
- 제 1항에 있어서,상기 하나 이상의 채널 간 연결점을 포함하는 유체채널 구조는 T, Y, 십자형태 또는 이들의 조합을 포함하는 연결점을 포함하는 것을 특징으로 하는 미세유체 시스템.
- 제 2항에 있어서,상기 유체채널 구조가 T 또는 Y 형태의 채널인 경우, 유체 정체점 부근에서의 캐비티를 포함하는 것을 특징으로 하는 미세유체 시스템.
- 제 3항에 있어서,상기 캐비티는 원형, 타원형, 길쭉한 슬릿, 정사각형, 직사각형, 사다리꼴, 다각형 및 이들의 조합과 그 변형된 형태를 포함하는 것을 특징으로 하는 미세유체 시스템.
- 제 3항에 있어서,상기 캐비티의 직경은 상기 세포의 직경에 따라 결정되는 것을 특징으로 하는 미세유체 시스템.
- 제 3항에 있어서,상기 캐비티는 상기 연결점에서 상기 용액의 세포와 채널벽간의 충돌시 상기 세포와 채널벽간 충돌면적을 없애거나 감소시키는 구조인 것을 특징으로 하는 미세유체 시스템.
- 제 1항 내지 제 6항 중 어느 한 항에 있어서, 상기 미세유체 시스템은,상기 유체채널 구조에서 용액을 흐르게 하는 유체제어수단을 더 포함하며,상기 유체제어수단은 상기 연결점 계면 근처에서 국소 와류를 발생시킬 수 있는 수준의 속도로 상기 용액을 상기 유체채널에서 흘리는 것을 특징으로 하는 미세유체 시스템.
- 제 7항에 있어서,상기 유체제어수단은 시린지 펌프 또는 공압시스템인 것을 특징으로 하는 미세유체 시스템.
- 제 1항 내지 제 8항 중 어느 한 항에 있어서,상기 용액의 레이놀즈 수(Re)는 1 내지 1000인 것을 특징으로 하는 미세유체 시스템.
- 제 9항에 있어서,상기 와류 특징은 상기 레이놀즈 수에 따라 결정되는 것을 특징으로 하는 미세유체 시스템.
- 제 1항 내지 제 8항 중 어느 한 항에 있어서,상기 와류는 닫힌 또는 개방된 재순환 흐름 형태인 것을 특징으로 하는 미세유체 시스템.
- 제 1항 내지 제 8항 중 어느 한 항에 있어서,상기 유체채널은 적어도 용액 입구와 출구 사이의 채널에서 복수 개의 연결점을 갖는 것을 특징으로 하는 미세유체 시스템.
- 제 10항에 있어서, 상기 미세유체 시스템은제 1항 내지 제 12항 중 어느 한 항에 따른 시스템이 직렬, 병렬 또는 이들의 조합 방식으로 결합된 것을 특징으로 미세유체 시스템.
- 관성을 이용한 세포 천공에 의하여 외부 물질을 새포 내로 전달하는 방법으로,상기 세포와 외부물질을 포함하는 용액을 유체채널로 연속적으로 흘리는 단계;상기 연결점 근처에서 와류생성수단에 의하여 와류를 형성시키는 단계;상기 와류에 의하여 상기 세포가 변형되는 단계; 및상기 세포 변형에 의하여 세포막에 생성되는 천공을 통하여 상기 외부 물질이 상기 세포 내로 도입되는 단계를 포함하는 것을 특징으로 하는, 관성을 이용한 세포 천공에 의하여 외부 물질을 새포 내로 전달하는 방법.
- 제 14항에 있어서,상기 와류생성수단은 상기 유체채널의 연결점 구조인 것을 특징으로 하는, 관성을 이용한 세포 천공에 의하여 외부 물질을 새포 내로 전달하는 방법.
- 제 15항에 있어서,상기 유체채널은 T, Y, 십자형태 또는 이들의 조합을 포함하는 연결점을 포함하는 것을 특징으로 하는, 관성을 이용한 세포 천공에 의하여 외부 물질을 새포 내로 전달하는 방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021554994A JP7353381B2 (ja) | 2019-03-12 | 2020-03-11 | 細胞内物質伝達のためのマイクロ流体システムおよび方法 |
US17/437,984 US20220177819A1 (en) | 2019-03-12 | 2020-03-11 | Microfluidic system for intracellular delivery of materials and method therefor |
AU2020234406A AU2020234406A1 (en) | 2019-03-12 | 2020-03-11 | Microfluidic system for intracellular delivery of materials and method therefor |
CN202080034645.0A CN113840657B (zh) | 2019-03-12 | 2020-03-11 | 用于材料的细胞内输送的微流体系统及其方法 |
EP20770856.1A EP3939701A4 (en) | 2019-03-12 | 2020-03-11 | MICROFLUID SYSTEM FOR INTRACELLULAR DELIVERY OF SUBSTANCES AND METHOD THEREOF |
CA3133045A CA3133045A1 (en) | 2019-03-12 | 2020-03-11 | Microfluidic system for intracellular delivery of materials and method therefor |
AU2023229574A AU2023229574A1 (en) | 2019-03-12 | 2023-09-15 | Microfluidic system for intracellular delivery of materials and method therefor |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0028069 | 2019-03-12 | ||
KR20190028069 | 2019-03-12 | ||
KR1020190134094A KR102354673B1 (ko) | 2019-03-12 | 2019-10-25 | 관성을 기반으로 한 세포 내 전달 미세 유체 플랫폼 |
KR10-2019-0134095 | 2019-10-25 | ||
KR10-2019-0134094 | 2019-10-25 | ||
KR1020190134095A KR102217407B1 (ko) | 2019-03-12 | 2019-10-25 | 관성을 기반으로 한 세포 내 전달 미세 유체 플랫폼 및 이를 이용한 세포 내 물질 전달방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020184992A1 true WO2020184992A1 (ko) | 2020-09-17 |
Family
ID=72427695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/003411 WO2020184992A1 (ko) | 2019-03-12 | 2020-03-11 | 세포 내 물질 전달을 위한 미세유체 시스템 및 방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220177819A1 (ko) |
EP (1) | EP3939701A4 (ko) |
JP (1) | JP7353381B2 (ko) |
CN (1) | CN113840657B (ko) |
AU (1) | AU2023229574A1 (ko) |
WO (1) | WO2020184992A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140287509A1 (en) | 2011-10-17 | 2014-09-25 | Massachusetts Institute Of Technology | Intracellular Delivery |
KR101515394B1 (ko) * | 2014-06-09 | 2015-05-04 | 연세대학교 산학협력단 | 세포 용해 미세유체 장치 및 이를 이용한 세포 용해 방법 |
JP2016526923A (ja) * | 2013-08-07 | 2016-09-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | マイクロ流体ボルテックス支援電気穿孔システム及び方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092727A1 (en) * | 2002-11-13 | 2004-05-13 | Biopharm Solutions Inc. | Cochleates without metal cations as bridging agents |
JP4692983B2 (ja) * | 2004-07-12 | 2011-06-01 | 独立行政法人科学技術振興機構 | リポソーム封入物質がエンドソームから脱出可能なリポソーム |
CA2809877C (en) * | 2010-09-14 | 2021-11-23 | The Regents Of The University Of California | Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices |
WO2016011059A1 (en) * | 2014-07-14 | 2016-01-21 | President And Fellows Of Harvard College | Drug cocktail analyses using microscale vortex-assisted electroporation |
RU2739794C2 (ru) * | 2014-10-31 | 2020-12-28 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
CN107002089B (zh) * | 2014-11-14 | 2021-09-07 | 麻省理工学院 | 化合物和组合物向细胞中的破坏和场实现的递送 |
US10441545B2 (en) * | 2014-12-16 | 2019-10-15 | Juvic Inc. | Microcellular microstructure and method for manufacturing same |
CA2973117C (en) * | 2015-01-07 | 2019-04-16 | Indee. Inc. | A method for mechanical and hydrodynamic microfluidic transfection and apparatus therefor |
CN104758952B (zh) * | 2015-03-10 | 2017-08-29 | 中国药科大学 | 共递送药物和基因的纳米载体及其制备方法和用途 |
EP3334776A4 (en) * | 2015-08-13 | 2019-03-27 | The Johns Hopkins University | METHOD FOR PRODUCING POLYELECTROLYTE COMPLEX NANOPARTICLES |
KR101605701B1 (ko) * | 2015-09-07 | 2016-04-01 | 한국과학기술원 | 미세액적 기반 바이오물질의 분석 장치 및 방법 |
WO2017066624A1 (en) * | 2015-10-15 | 2017-04-20 | President And Fellows Of Harvard College | Cell immortalization via vortex electroporation gene delivery |
-
2020
- 2020-03-11 US US17/437,984 patent/US20220177819A1/en active Pending
- 2020-03-11 WO PCT/KR2020/003411 patent/WO2020184992A1/ko unknown
- 2020-03-11 EP EP20770856.1A patent/EP3939701A4/en active Pending
- 2020-03-11 JP JP2021554994A patent/JP7353381B2/ja active Active
- 2020-03-11 CN CN202080034645.0A patent/CN113840657B/zh active Active
-
2023
- 2023-09-15 AU AU2023229574A patent/AU2023229574A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140287509A1 (en) | 2011-10-17 | 2014-09-25 | Massachusetts Institute Of Technology | Intracellular Delivery |
KR20140116374A (ko) * | 2011-10-17 | 2014-10-02 | 메사추세츠 인스티튜트 오브 테크놀로지 | 세포 내 전달 |
JP2016526923A (ja) * | 2013-08-07 | 2016-09-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | マイクロ流体ボルテックス支援電気穿孔システム及び方法 |
KR101515394B1 (ko) * | 2014-06-09 | 2015-05-04 | 연세대학교 산학협력단 | 세포 용해 미세유체 장치 및 이를 이용한 세포 용해 방법 |
Non-Patent Citations (2)
Title |
---|
JUSTIN A. JARRELL, AMYA.TWITE, KATHERINE H.W. J. LAU, MOEIN N. KASHANI, ADRIANA. LIEVANO, JULYANAACEVEDO, CRAIG PRIEST, JORGE NIE: "Intracellular Delivery of mRNA to Human Primary T Cells With Microfluidic Vortex Shedding", SCIENTIFIC REPORTS, vol. 9, 3214, 2019, pages 1 - 11, XP055740840 * |
YANXIANG DENG, MEGAN KIZER, MIRAN RADA, JESSICA SAGE, XING WANG, DONG-JOO CHEON, ARAM J. CHUNG: "Intracellular Delivery of Nanomaterials via an Inertial Microfluidic Cell Hydroporator", NANOLETTERS, vol. 18, no. 4, 2018, pages 2705 - 2710, XP055740558 * |
Also Published As
Publication number | Publication date |
---|---|
EP3939701A4 (en) | 2023-05-10 |
CN113840657A (zh) | 2021-12-24 |
EP3939701A1 (en) | 2022-01-19 |
AU2023229574A1 (en) | 2023-10-05 |
US20220177819A1 (en) | 2022-06-09 |
JP2022528826A (ja) | 2022-06-16 |
CN113840657B (zh) | 2023-04-14 |
JP7353381B2 (ja) | 2023-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2964138C (en) | Disruption and field enabled delivery of compounds and compositions into cells | |
EP3985096A1 (en) | Method and device for controlling movement of micro-particles in solution using ultra-high frequency sound wave | |
Li et al. | Lipoplex‐mediated single‐cell transfection via droplet microfluidics | |
Kizer et al. | Hydroporator: a hydrodynamic cell membrane perforator for high-throughput vector-free nanomaterial intracellular delivery and DNA origami biostability evaluation | |
JP7084393B2 (ja) | 対流駆動細胞内輸送のための方法 | |
Kim et al. | Microfluidic approaches for gene delivery and gene therapy | |
Wu et al. | Ferrofluid droplet formation and breakup dynamics in a microfluidic flow-focusing device | |
US9816086B2 (en) | Dose and location controlled drug/gene/particle delivery to individual cells by nanoelectroporation | |
US9192944B2 (en) | Methods, systems and apparatus for size-based particle separation | |
US20230219086A1 (en) | Method and device for cell or microvesicle isolation | |
Jokilaakso et al. | Ultra-localized single cell electroporation using silicon nanowires | |
CA2973117A1 (en) | A method for mechanical and hydrodynamic microfluidic transfection and apparatus therefor | |
WO2020184992A1 (ko) | 세포 내 물질 전달을 위한 미세유체 시스템 및 방법 | |
JP2005037346A (ja) | マイクロ流体制御システム | |
Matsumoto et al. | Mechanoporation of living cells for delivery of macromolecules using nanoneedle array | |
Deng et al. | Wetting-induced coalescence of nanoliter drops as microreactors in microfluidics | |
Vitor et al. | Tracking the evolution of transiently transfected individual cells in a microfluidic platform | |
Jürgens et al. | Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques–an evaluation of particle properties and efficiency | |
CA3133045A1 (en) | Microfluidic system for intracellular delivery of materials and method therefor | |
WO2022220539A1 (ko) | 세포 내 물질 전달 플랫폼 | |
WO2016003212A1 (ko) | 온도에 따라 가역적으로 계면특성 조절이 가능한 비구형 양친성 이량체 나노입자, 이의 제조방법 및 이를 포함하는 조성물 | |
JP6864287B2 (ja) | 細胞質の交換方法、細胞の製造方法、及び装置 | |
WO2016099190A1 (ko) | 점도 측정 장치 | |
Kang et al. | Optimization of a microfluidic device for localized electroporation of cells | |
WO2024071987A1 (ko) | 미세 유체 혼합용 구조체 및 이를 구비한 미세 유체 혼합 장치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20770856 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3133045 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021554994 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020770856 Country of ref document: EP Effective date: 20211012 |
|
ENP | Entry into the national phase |
Ref document number: 2020234406 Country of ref document: AU Date of ref document: 20200311 Kind code of ref document: A |